Thursday, February 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Three Doses of mRNA COVID-19 Vaccines Effective Against Hospitalizations for Omicron and Delta

by Global Biodefense Staff
January 21, 2022
Three Doses of mRNA COVID-19 Vaccines Effective Against Hospitalizations for Omicron and Delta

A corpsman screens a patient prior to administering a dose of the COVID-19 vaccine at Walter Reed National Medical Center. Credit: Elizabeth Kearns

A nationwide study from the Centers for Disease Control and Prevention (CDC) has found that mRNA booster shots (either Pfizer or Moderna) are 82 percent effective in protecting against COVID-19 Omicron variant-associated emergency department (ED) visits and 90 percent effective in protecting against COVID-19 Omicron variant-related hospitalizations.

The value of the third dose of an mRNA vaccine is significant as two doses were only 38 percent effective in protecting against Omicron-related ED visits and only 57 percent effective in protecting against COVID-19 Omicron variant-related hospitalizations.

“These findings underscore the importance of receiving a third dose of mRNA COVID-19 vaccine to prevent both moderately severe and severe COVID-19, especially while the Omicron variant is the predominant circulating variant and when the effectiveness of 2 doses of mRNA vaccines is significantly reduced against this variant.”

Boosters were even more effective against the Delta variant of COVID-19, protecting against 94 percent of both COVID-19 Delta variant associated ED visits and hospitalizations.

“Our findings provide important evidence that  booster shots are highly effective  and those who are unvaccinated are at significantly greater risk of experiencing more severe COVID-19 outcomes and should get vaccinated and boostered as soon as possible” said study co-author Shaun Grannis, M.D., M.S., vice president for data and analytics at Regenstrief Institute and professor of family medicine at Indiana University School of Medicine. “As we look at the high positivity rates across the nation, there is a silver lining. We have yet more evidence that vaccines and boosters offer protection against severe disease, including Omicron-related illness.”

The CDC collaborated with six U.S. healthcare systems plus the Regenstrief Institute, to create the VISION network to assess COVID-19 vaccine effectiveness.  In addition to Regenstrief Institute, other members are Columbia University Irving Medical Center, HealthPartners, Intermountain Healthcare, Kaiser Permanente Northern California, Kaiser Permanente Northwest and University of Colorado. Regenstrief contributes data and expertise to the VISION Network. Authors of the study are from 10 states and 14 institutions, including the public sector, research, clinical and academia.

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. Early Release / January 21, 2022.

Tags: COVID-19Editor PickmRNAOmicronVaccines

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy